Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CRYVT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DP-303c
|
|||||
| Synonyms |
DP 303c; DP303c
Click to Show/Hide
|
|||||
| Organization |
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.; CSPC Pharmaceutical Group Ltd.
|
|||||
| Drug Status |
Phase 3
|
|||||
| Indication |
In total 5 Indication(s)
HER2(+) breast cancer [ICD11:2C60-2C65]
Phase 3
Gastric cancer [ICD11:2B72]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
HER2(+) solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Salivary gland tumor [ICD11:2E91]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
DP001
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PEG2-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the glutamine 295 by an engineered transglutaminase (mTgase).
|
|||||
| Drugbank ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05334810 | Clinical Status | Phase 2 | ||
| Clinical Description | A multi-center, open-lable, single-arm phase 2 study to evaluate the efficacy and safety of DP303c in patients with HER2-positive unresectable locally advanced, relapsed, or metastatic breast cancer. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04828616 | Clinical Status | Phase 2 | ||
| Clinical Description | An open-label, multicentre, phase 2 study of DP303c injection in patients with HER2-expressing advanced ovarian cancer. | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04826107 | Clinical Status | Phase 2 | ||
| Clinical Description | An open-label, multicentre, phase 2 study of DP303c injection in patients with unresectable locally advanced, recurrent or metastatic gastric cancer with HER2 expression. | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04146610 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1a, multicenter, open and dose-increasing study of DP303c to evaluate the safety , pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive advanced solid tumors. | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 7.60% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
DP001 (10 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 16.20% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
T-DM1 (10 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 28.47% (Day 18) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP001 (10 mg/kg).
|
||||
| In Vivo Model | SK-OV-3 cell line xenograft model | ||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 33.60% (Day 25) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP001 (10 mg/kg).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 39.00% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
DP303c (0.3 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.26% (Day 18) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (1 mg/kg).
|
||||
| In Vivo Model | SK-OV-3 cell line xenograft model | ||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 54.40% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 0.1 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.10% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 1 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.94% (Day 18) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (3 mg/kg).
|
||||
| In Vivo Model | SK-OV-3 cell line xenograft model | ||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.48% (Day 21) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP001 (15 mg/kg).
|
||||
| In Vivo Model | HCC1954 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.60% (Day 25) | High HER2 expression (HER2+++/++) | ||
| Method Description |
T-DM1 (10 mg/kg).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.00% (Day 25) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (10 mg/kg).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.00% (Day 25) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (2.5 mg/kg).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.00% (Day 25) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (5 mg/kg).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.10% (Day 18) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 3 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.16% (Day 18) | High HER2 expression (HER2+++/++) | ||
| Method Description |
T-DM1 (10 mg/kg).
|
||||
| In Vivo Model | SK-OV-3 cell line xenograft model | ||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.30% (Day 21) | High HER2 expression (HER2+++/++) | ||
| Method Description |
T-DM1 (15 mg/kg).
|
||||
| In Vivo Model | HCC1954 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.00% (Day 21) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (10 mg/kg).
|
||||
| In Vivo Model | HCC1954 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.00% (Day 21) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (15 mg/kg).
|
||||
| In Vivo Model | HCC1954 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.00% (Day 21) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (3 mg/kg).
|
||||
| In Vivo Model | HCC1954 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.10% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 3 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.50% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 2.5 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.50% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 10 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.80% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 5 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.80% (Day 18) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 10 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.80% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 1 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.50% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 10 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.54% (Day 18) | High HER2 expression (HER2+++/++) | ||
| Method Description |
DP303c (10 mg/kg).
|
||||
| In Vivo Model | SK-OV-3 cell line xenograft model | ||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.80% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 3 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.10% (Day 25) | High HER2 expression (HER2+++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 15 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.90% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
Pathogen-free female nude mice were injected subcutaneously with each cell suspension. According to tumor volumes,the mice were randomly divided in two groups: treatment and control groups. Each drug was given to the animals intravenously. The dosing frequency was once a week (qw), qw 2 or qw 3.DP303c induced obvious tumor growth inhibition at a single dose of 10 mg/kg.
Click to Show/Hide
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
DP303c (1 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
DP303c (10 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 34 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 32) | Moderate HER2 expression (HER2++) | ||
| Method Description |
DP303c (3 mg/kg).
|
||||
| In Vivo Model | JIMT -1 cell line xenograft model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.07 nM | Moderate HER2 expression (HER2++; HER2 MFI=157,231) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.07 nM | High HER2 expression (HER2+++) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1 x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1 x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.08 nM | High HER2 expression (HER2+++; HER2 MFI=987,353) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.08 nM | Negative HER2 expression (HER2-; HER2 MFI=256) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1 x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.15 nM | High HER2 expression (HER2+++) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.15 nM | High HER2 expression (HER2+++) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1 x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1 x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.22 nM | Negative HER2 expression (HER2-) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.22 nM | High HER2 expression (HER2+++) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1 x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1 x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | High HER2 expression (HER2+++; HER2 MFI=804,573) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | High HER2 expression (HER2+++; HER2 MFI=892,333) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1 x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1 x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.39 nM | High HER2 expression (HER2+++) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.39 nM | Moderate HER2 expression (HER2++) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 50.00 nM | High HER2 expression (HER2+++; HER2 MFI=1,106,494) | ||
| Method Description |
To obtain a single-cell suspension, the cells were harvested and resuspended. The cell density was adjusted to 1x105 cells/mL and seeded in a 96-well cell culture plate at 100 uL/well (1x104 cells/well). DP303c labeled with DyLight 488 was added into the 96-well plate with a final concentration of 2 ug/mL.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000.00 nM | High HER2 expression (HER2+++; HER2 MFI=765,629) | ||
| Method Description |
Comparison of in vitro Activity Between DP303c and T -DM1 in Variable HER2 Cell Lines.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.